Up-regulation of IGF-1, RANTES and VEGF in patients with anti-centromere antibody-positive early/mild systemic sclerosis
Up-regulation of IGF-1, RANTES and VEGF in patients with anti-centromere antibody-positive early/mild systemic sclerosis
复制标题
DOI：
10.1080/14397595.2020.1726599
复制
发表时间：
2020-02-15
影响因子：
2.2
通讯作者：
Fujii, Takao
中科院分区：
文献类型：
--
作者：
Tabata, Kayoko;Mikita, Naoya;Fujii, Takao
目的：多种细胞因子网络可能控制系统性硬化症（SSc）患者血管病变的发病机制。我们的目的是比较不同临床阶段 SSc 患者的血管生成细胞因子谱。方法：将9例疑似SSc并诊断为SSc的抗着丝粒抗体（ACA）患者根据ACR/EULAR2013分类标准或ACR1980初步分类分为三组（组1：SSc临床前阶段、组2：轻度/早期SSc和组3：典型lcSSc），并采集血清样本。我们通过膜阵列评估了 20 种细胞因子的表达水平。结果：第2组EGF、ENA-78、bFGF、IGF-I、IL-8、MCP-1、TGF-β1、血小板生成素、VEGF、VEGF-D平均值较第1组增加两倍以上。组1与组2血清IGF-1、RANTES、VEGF水平差异有统计学意义。组1和组3之间VEGF值也有显着性差异。血清 IGF-1 和 RANTES 水平之间存在轻度和显着相关性 (r = 0.721，p = .028)。结论：IGF-1、RANTES和VEGF被认为参与了从临床前SSc到早期/轻度SSc的疾病发展。因此，这些细胞因子可用作早期诊断的生物标志物。
Objective: Multiple cytokine network may control the pathogenesis of vasculopathy in patients with systemic sclerosis (SSc). We aimed at comparing angiogenic cytokine profile among SSc patients at various clinical stage. Methods: We divided nine patients with anti-centromere antibody (ACA) who were suspected of SSc and diagnosed as having SSc into three groups (group1: pre-clinical stage of SSc, group2: mild/early SSc and group3: typical lcSSc) according to the ACR/EULAR2013 classification criteria or ACR1980 preliminary classification, and serum sample were obtained from them. We evaluated the expression levels of 20 cytokines by membrane array. Results: Average values of EGF, ENA-78, bFGF, IGF-I, IL-8, MCP-1, TGF-beta 1, thrombopoietin, VEGF and VEGF-D in group2 were increased compared as those of group1 more than twofold. Statistically significant difference was found in serum levels of IGF-1, RANTES and VEGF between group1 and group2. There was also significant difference in the value of VEGF between group1 and group3. There were mild and significant correlations between serum IGF-1 and RANTES levels (r = 0.721, p = .028). Conclusion: IGF-1, RANTES and VEGF are thought to be involved in the disease development from pre-clinical stage of SSc to early/mild SSc. Thus, these cytokines may be utilized as a biomarker for early diagnosis.